[
    [
        {
            "time": "2021-11-24",
            "original_text": "复星医药参设多个基金加强布局大健康产业 阿里健康中期亏损2.32亿元",
            "features": {
                "keywords": [
                    "复星医药",
                    "投资基金",
                    "大健康产业",
                    "阿里健康",
                    "中期亏损"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "大健康"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复星医药参设多个基金加强布局大健康产业 阿里健康中期亏损2.32亿元",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-24",
            "original_text": "复星医药：设立安吉及徐州投资基金，计划募集资金均为5亿元",
            "features": {
                "keywords": [
                    "复星医药",
                    "安吉基金",
                    "徐州基金",
                    "募集资金"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "大健康"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药：设立安吉及徐州投资基金，计划募集资金均为5亿元",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-11-24",
            "original_text": "复星医药：成立合伙企业",
            "features": {
                "keywords": [
                    "复星医药",
                    "合伙企业"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药：成立合伙企业",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-11-24",
            "original_text": "复星医药：董事会建议销售交易年度上限调整为7.5亿元",
            "features": {
                "keywords": [
                    "复星医药",
                    "销售交易",
                    "年度上限",
                    "调整"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药：董事会建议销售交易年度上限调整为7.5亿元",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-24",
            "original_text": "复星医药（02196）：‘18复药02’将于11月30日付息",
            "features": {
                "keywords": [
                    "复星医药",
                    "债券付息",
                    "18复药02"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药（02196）：‘18复药02’将于11月30日付息",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-11-24",
            "original_text": "复星医药（02196）及控股子公司拟与宁波星曜共同投资设立股权投资基金大连复健",
            "features": {
                "keywords": [
                    "复星医药",
                    "股权投资基金",
                    "大连复健"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "大健康"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药（02196）及控股子公司拟与宁波星曜共同投资设立股权投资基金大连复健",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-24",
            "original_text": "中山公用：股东复星集团拟减持不超6%公司股份",
            "features": {
                "keywords": [
                    "中山公用",
                    "复星集团",
                    "减持"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "中山公用：股东复星集团拟减持不超6%公司股份",
                "Correlation": 6,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-24",
            "original_text": "为持续加强对前沿创新药研发项目的早期介入 复星医药（600196.SH）拟参设基金",
            "features": {
                "keywords": [
                    "复星医药",
                    "创新药",
                    "早期介入",
                    "基金"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "创新药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "为持续加强对前沿创新药研发项目的早期介入 复星医药（600196.SH）拟参设基金",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]